Comparative study of ibuproxam complexation with amorphous beta-cyclodextrin derivatives in solution and in the solid state.
The complexing, solubilizing and amorphizing abilities toward ibuproxam (a poorly water-soluble anti-inflammatory agent) of some randomly substituted amorphous beta-cyclodextrin derivatives (i.e. methyl- (MebetaCd), hydroxyethyl- (HEbetaCd), and hydroxypropyl- (HPbetaCd) beta-cyclodextrins) were investigated and compared with those of the parent beta-cyclodextrin. Equimolar drug-cyclodextrin solid systems were prepared by blending, cogrinding, coevaporation, and colyophilization. Drug-carrier interactions were studied in both the liquid and solid state by phase solubility analysis, supported by molecular modelling, differential scanning calorimetry, X-ray powder diffractometry, Fourier transform infrared spectroscopy and scanning electron microscopy. All the betaCd derivatives showed greater solubilizing efficacies toward ibuproxam than the parent one, due to their higher water solubility. On the contrary, a clear reduction of complexing ability was observed, indicative of some steric interferences to drug inclusion due to the presence of substituents, as confirmed by molecular modelling studies. However, this negative effect was not reflected in the dissolution behaviour (evaluated according to the dispersed amount method) of their solid binary systems, probably thanks to the greater amorphizing properties shown (DSC and X-ray analyses) by betaCd derivatives. In fact their dissolution efficiencies were not significantly different (MebetaCd) or only slightly lower (HEbetaCd and HPbetaCd) than those of the corresponding products with beta-cyclodextrin. Colyophilized products were in all cases the most effective, followed by coground and coevaporated systems, whose dissolution efficiencies were over four times higher than the corresponding physical mixtures and about 15 times higher than the pure drug.
Dipartimento di Scienze Farmaceutiche, Facoltà di Farmacia, Università di Firenze, Florence, Italy. mura@farmfi.scifarth.unifi.it
Paola
P
Mura
Naima
N
Zerrouk
M
M
Faucci
Francesca
F
Maestrelli
Chantal
C
Chemtob
D000073738:2-Hydroxypropyl-beta-cyclodextrin; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000737:chemistry*; D044482:Benzeneacetamides; D002152:Calorimetry, Differential Scanning; D003505:Cyclodextrins / Q000737:chemistry*; D004344:Drug Incompatibility; D005079:Excipients / Q000737:chemistry*; D006877:Hydroxamic Acids / Q000737:chemistry*; D008855:Microscopy, Electron, Scanning; D008958:Models, Molecular; D012996:Solutions; D017550:Spectroscopy, Fourier Transform Infrared; D014961:X-Ray Diffraction; D047392:beta-Cyclodextrins
D000894:Anti-Inflammatory Agents, Non-Steroidal; D044482:Benzeneacetamides; D003505:Cyclodextrins; D005079:Excipients; D006877:Hydroxamic Acids; D012996:Solutions; D047392:beta-Cyclodextrins; C108732:methyl-beta-cyclodextrin; D000073738:2-Hydroxypropyl-beta-cyclodextrin; C059250:2-hydroxyethyl-beta-cyclodextrin; C031215:betadex; C025377:ibuproxam